Company Performance Metrics
- Svante Almkvist: Senior CMC Consultant
- Hans Basun: Vice President Clinical Development and Chief Medical Officer
BioArctic is a Swedish research-oriented biopharma company. The company was founded in 2003 by Professor Lars Lannfelt and Dr. Pär Gellerfors to develop important breakthrough discoveries made by Professor Lannfelt regarding Alzheimer’s disease. These discoveries – the Swedish mutation and the Arctic mutation – have attracted much attention
internationally and explain the central role of amyloid-beta in Alzheimer’s disease, which has led to the development of new treatment strategies.
BioArctic has developed a proprietary technology platform that has proven to be successful when the company’s first drug candidate antibody BAN2401 for Alzheimer´s disease was developed.
The company’s technology is now also used for other diseases of the Central Nervous System such as Parkinson’s disease (BioArctic’s antibody BAN0805) and also for related diagnostics and technology.
